مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

509
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

0
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

EVALUATION OF LONG-TERM EFFECT OF ADDING LOW-DOSE DACLIZUMAB TO STANDARD PROTOCOL ON KIDNEY REJECTION IN KIDNEY RECIPIENTS

Pages

  425-434

Abstract

 Background & Aims: DACLIZUMAB is a monoclonal antibody directed against CD25 subunit of interlukin 2 receptor. Several studies have shown the effectiveness of DACLIZUMAB on reduction of acute rejection in RENAL TRANSPLANTATION with regular or limited dose. The present study assessed the outcomes of 3 and 5 years follow-up of a prospective case-control trial comparing safety and efficacy of induction therapy with two doses of DACLIZUMAB, compared with no induction treatment, in renal transplant recipients.Methods: This clinical-trial study was started in 2006 on 140 living donor kidney recipients admitted to kidney transplant ward of Kerman Afzalipour hospital, Iran. These patients were randomly assigned into two 70 patients, intervention and control groups. All patients received cyclosporine, mycophenolate mofetil and prednisolone. Intervention group recieved DACLIZUMAB at a dose of 1 mg/kg before transplantation and then two weeks later, also. All patients were followed up for 3 and 5 years for graft and patient survival and side effect of DACLIZUMAB, so.Results: After 3 years, 58 patients remained in case and 61 in control group. Function of transplanted kidney was evaluated on base of calculated glomerular filtration rate (GFR), and after 3 and 5 years, were same between two groups. Rate of SEPSIS was same between two groups but infection with varicella zuster, in first 6 months after transplantation, was significantly more in intervention group (P = 0.04).Conclusion: DACLIZUMAB did not have any effect on patient or GRAFT SURVIVAL. It did not increase the rate of SEPSIS but might increase the rate of varicella zuster infection.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    AZMANDIAN, J., RAHIMI, N., SOHREVARDI, S.M., ETMINAN, A., FAZELI, F., AZIZISHOUL, S., & SHAFII, Z.. (2013). EVALUATION OF LONG-TERM EFFECT OF ADDING LOW-DOSE DACLIZUMAB TO STANDARD PROTOCOL ON KIDNEY REJECTION IN KIDNEY RECIPIENTS. JOURNAL OF KERMAN UNIVERSITY OF MEDICAL SCIENCES, 20(5), 425-434. SID. https://sid.ir/paper/61/en

    Vancouver: Copy

    AZMANDIAN J., RAHIMI N., SOHREVARDI S.M., ETMINAN A., FAZELI F., AZIZISHOUL S., SHAFII Z.. EVALUATION OF LONG-TERM EFFECT OF ADDING LOW-DOSE DACLIZUMAB TO STANDARD PROTOCOL ON KIDNEY REJECTION IN KIDNEY RECIPIENTS. JOURNAL OF KERMAN UNIVERSITY OF MEDICAL SCIENCES[Internet]. 2013;20(5):425-434. Available from: https://sid.ir/paper/61/en

    IEEE: Copy

    J. AZMANDIAN, N. RAHIMI, S.M. SOHREVARDI, A. ETMINAN, F. FAZELI, S. AZIZISHOUL, and Z. SHAFII, “EVALUATION OF LONG-TERM EFFECT OF ADDING LOW-DOSE DACLIZUMAB TO STANDARD PROTOCOL ON KIDNEY REJECTION IN KIDNEY RECIPIENTS,” JOURNAL OF KERMAN UNIVERSITY OF MEDICAL SCIENCES, vol. 20, no. 5, pp. 425–434, 2013, [Online]. Available: https://sid.ir/paper/61/en

    Related Journal Papers

    Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button